Policy changes Backwork has recorded, newest first. The most recent change on record is from October 14, 2026. Changes appear here after Backwork reviews and applies a refresh, so this page can trail the payers’ own sites.
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
83,427 on record
| Recorded | Payer | Policy | Change |
|---|---|---|---|
| Aug 2, 2026 | Point32Health | Dupixent (dupilumab) | New policy |
| Aug 2, 2026 | Point32Health | Dupixent (dupilumab) | New policy |
| Aug 2, 2026 | Point32Health | Dupixent (dupilumab) | New policy |
| Aug 2, 2026 | Point32Health | Droxidopa | New policy |
| Aug 2, 2026 | Point32Health | Doxylamine-pyridoxine (Diclegis) tablets | New policy |
| Aug 2, 2026 | Point32Health | Dojolvi (triheptanoin) | New policy |
| Aug 2, 2026 | Point32Health | Dipeptidyl Peptidase-4 (DPP-4) Inhibitors | New policy |
| Aug 2, 2026 | Point32Health | Dificid (fidaxomicin) | New policy |
| Aug 2, 2026 | Point32Health | Dificid (fidaxomicin) | New policy |
| Aug 2, 2026 | Point32Health | Dermatological Immunomodulators | New policy |
| Aug 2, 2026 | Point32Health | Denavir (penciclovir) cream | New policy |
| Aug 2, 2026 | Point32Health | Daraprim (pyrimethamine) | New policy |
| Aug 2, 2026 | Point32Health | Cystic Fibrosis Medications | New policy |
| Aug 2, 2026 | Point32Health | Cystic Fibrosis Medications | New policy |
| Aug 2, 2026 | Point32Health | Cushing’s Disease Agents: Korlym (mifepristone), Recorlev (levoketoconazole) | New policy |
| Aug 2, 2026 | Point32Health | Cushing’s Disease Agents | New policy |
| Aug 2, 2026 | Point32Health | Cresemba (isavuconazonium) capsule | New policy |
| Aug 2, 2026 | Point32Health | Crenessity (crinecerfont) oral suspension and tablets | New policy |
| Aug 2, 2026 | Point32Health | Crenessity (crinecerfont) oral suspension and tablets | New policy |
| Aug 2, 2026 | Point32Health | Cosentyx (secukinumab) | New policy |
| Aug 2, 2026 | Point32Health | Corticosteroid medications, topical | New policy |
| Aug 2, 2026 | Point32Health | Corlanor (ivabradine) | New policy |
| Aug 2, 2026 | Point32Health | Continuous Glucose Monitoring Systems – Dexcom G6 and G7 Systems | New policy |
| Aug 2, 2026 | Point32Health | Compounded Medications | New policy |
| Aug 2, 2026 | Point32Health | Compound Medications | New policy |
| Aug 2, 2026 | Point32Health | Cinacalcet | New policy |
| Aug 2, 2026 | Point32Health | Cimzia (certolizumab pegol) | New policy |
| Aug 2, 2026 | Point32Health | Cibinqo (abrocitinib) | New policy |
| Aug 2, 2026 | Point32Health | Cholbam (cholic acid) | New policy |
| Aug 2, 2026 | Point32Health | Chelating and Reducing Agents | New policy |
| Aug 2, 2026 | Point32Health | Cerdelga (eliglustat) | New policy |
| Aug 2, 2026 | Point32Health | Cardamyst (etripamil) | New policy |
| Aug 2, 2026 | Point32Health | Carbaglu (carglumic acid) | New policy |
| Aug 2, 2026 | Point32Health | Calcipotriene 0.005%/betamethasone dipropionate 0.064% (Taclonex) | New policy |
| Aug 2, 2026 | Point32Health | COMT Inhibitors | New policy |
| Aug 2, 2026 | Point32Health | CNS Stimulant Medications | New policy |
| Aug 2, 2026 | Point32Health | Bylvay (odevixibat) | New policy |
| Aug 2, 2026 | Point32Health | Buspirone | New policy |
| Aug 2, 2026 | Point32Health | Buprenorphine/Naloxone Medications (Zubsolv) | New policy |
| Aug 2, 2026 | Point32Health | Buprenorphine Sublingual Tablets | New policy |
| Aug 2, 2026 | Point32Health | Budesonide Extended-Release Tablets and Capsules | New policy |
| Aug 2, 2026 | Point32Health | Brinsupri (brensocatib) | New policy |
| Aug 2, 2026 | Point32Health | Bimzelx (bimekizumab-bkzx) | New policy |
| Aug 2, 2026 | Point32Health | BiDil (isosorbide dinitrate) | New policy |
| Aug 2, 2026 | Point32Health | Besremi (ropeginterferon alfa-2b-njft) | New policy |
| Aug 2, 2026 | Point32Health | Besremi (ropeginterferon alfa-2) | New policy |
| Aug 2, 2026 | Point32Health | Bepreve (bepotastine) | New policy |
| Aug 2, 2026 | Point32Health | Bepreve (bepotastine) | New policy |
| Aug 2, 2026 | Point32Health | Benlysta (belimumab) Subcutaneous | New policy |
| Aug 2, 2026 | Point32Health | Benlysta (belimumab) Subcutaneous | New policy |